DMG, one of the world’s leading manufacturers of restorative materials and preventive products, has introduced a precision placement delivery system for a wide range of dental materials. The new Composite Dispenser is particularly effective with DMG’s Ecosite Bulk Fill composite.
Designed for the placement of dental materials precisely and accurately into the oral cavity, the ergonomic
Composite Dispenser will simplify the workflow of dental professionals. It allows for fast and easy placement of composites as well as other dental materials such as cements and glass ionomers. Additionally, it has comfortable handle grips and maneuvers easily while allowing for an effortless load.
DMG’s Composite Dispenser offers dental professionals:
• Quick, easy and precise placement of materials
• Convenient autoclaving for infection control
• Comfort and ease when holding and maneuvering
• Effortless loading
The combination of the Composite Dispenser and Ecosite Bulk Fill can have a significant synergistic effect on a practice’s productivity. Ecosite’s state-of-the-art technology avoids the two traditional drawbacks associated with bulk fill composites: short working time and sub-optimal esthetics. Instead, it offers a maximum depth of 5mm, a single 20-second composite cure, low shrinkage stress, and excellent adaptability, packability and handling. It also delivers high polishability, extra fluoride release and truly exceptional esthetics, and it does not require a capping layer or stick to instruments.
For more information about the DMG Composite Dispenser or Ecosite Bulk Fill, visit dmg-america.com.
About DMG America
DMG manufactures and distributes market-leading restorative materials and preventive products that are internationally recognized for their quality and innovation. Known for innovative material technology, including the flagship products Luxatemp, LuxaCore and the revolutionary Icon resin infiltrant, DMG is committed to helping the dental profession meet its materials needs through innovation, collaboration and dedication. For more information about DMG products, or to find a sales representative, visit them online at dmg-america.com or call (800) 662-6383.
The American Academy of Cosmetic Dentistry (AACD) recently recognized 12 dental professionals who have demonstrated their dedication to continuing education and responsible patient care by becoming credentialed by the AACD. This year, the AACD will honor eight newly Accredited Members and four newly Accredited Fellows during the 35th Annual AACD Scientific Session in San Diego.
AACD Accreditation is an honor and can only be achieved by completing a rigorous credentialing process including a written examination, the submission of clinical cases for peer-reviewed evaluation, and an oral examination. The Accreditation process, which was developed by the AACD and is the world’s most recognized advanced credentialing program, encourages further education, interaction with like-minded colleagues, and the opportunity for professional growth. Accreditation requires dedication to continuing education and responsible patient care.
The newly Accredited Members include: Vinay N. Chirnalli, DMD, AAACD; Ramon A. Duran, DMD, AAACD; Sandra M. Finch, DMD, AAACD; Ingrida Ivance, DDS, AAACD; Courtney L. Lavigne, DMD, AAACD; Roberto Palmieri, DMD, AAACD; Robert L. Rioseco, DMD, AAACD and Keerti S. Sahasrabudhe, DDS, AAACD.
“The time, commitment and dedication that's required to complete the Accreditation process is unrivaled. The sense of achievement that comes with it is indeed life changing. These newly Accredited members have completed this task and have so much to be proud of, as they have reached a level of dentistry that is desired by many and achieved by few,” notes AACD Accreditation Chair, Adamo Notarantonio, DDS, FAACD.
The AACD is also welcoming four new Accredited Fellows. The purpose of Fellowship is to provide the highest level of achievement for members in accordance with the AACD's mission of education and excellence.
AACD’s new Accredited Fellows include:
Adamo E. Notarantonio, DDS, FAACD, has been a member of the AACD since 2007 and achieved Accredited Member status in 2011. He is a 2002 graduate of the State University of New York at Stony Brook School of Dental Medicine, where he received honors in both removable and fixed prosthodontics. He completed his residency in the Advanced Education in General Dentistry Program at Stony Brook in 2003 and was chosen by faculty to complete a second year as Chief Resident. He currently serves as Accreditation Chairman, is on the American Board of Cosmetic Dentistry and volunteers for the AACD Charitable Foundation’s Give Back a Smile program.
Tara N. Hardin, DDS, FAACD, has been a member of the AACD since 2002 and achieved Accredited Member status in 2014. She graduated from Furman University with a Bachelor of Science Degree in 1996, then attended The Ohio State University where she received her DDS in 2000. Dr. Hardin is a Fellow of The Academy of General Dentistry, a member of the American Dental Association, along with several sleep organizations. She devotes countless hours of continuing education on facial esthetics, cosmetic dentistry, smile design, TMJ therapy, and sleep apnea.
Kathy S. Sanders, DMD, FAACD, has been a member of the AACD since 1998 and achieved Accredited Member status in 2006. She received her DMD from the Medical College of Georgia, Augusta and credits a presentation by AACD co-founder Dr. Jeff Morley as the beginning of her quest for cosmetic dental excellence. Since that time, she has participated in rigorous continuing education pursuits and advanced practicum experience taught by some of the world’s most talented cosmetic dentists. Dr. Sanders is a Give Back a Smile volunteer and was also recognized in 2015 with the Milligan College Leaders in Christian Service Award. She maintains a private practice in Kingsport, Tennessee.
Sandra Hulac, DDS, FAACD, was born in Munich, Germany into a family of dentists. She graduated top of her class from University of Witten/Herdecke dental school in 1993. After practicing for some time in London, Dr. Hulac relocated with her family to Hong Kong in 2001. In 2007, she co-founded Tam, Hulac & Partners, one of the few interdisciplinary dental practices in Hong Kong. In addition to achieving Accredited Fellow status in the AACD, Dr. Hulac has also published several articles in industry publications worldwide.
“These dental professionals’ commitment to responsible esthetics and cosmetic dentistry is undeniable with their most recent achievement as AACD Accredited Fellows,” said AACD Fellowship Chair Bradley J. Olson, DDS, FAACD. “Our Accredited Fellow members must complete one of the most rigorous, yet life-changing journeys of their career—and of their lives.”
These newly credentialed dental professionals will be recognized and receive their awards during special ceremonies at the 35th Annual AACD Scientific Session held April 24 – 27, in San Diego.
For more information about AACD’s credentialing programs, visit www.aacd.com/accreditationfellowship.
About the AACD
The AACD is the world’s largest non-profit member organization dedicated to advancing excellence in comprehensive oral care, combining art and science to optimally improve dental health, esthetics, and function. Comprised of more than 5,000 cosmetic dental professionals in 70 countries worldwide, the AACD fulfills its mission by offering superior educational opportunities, promoting and supporting a respected Accreditation credential, serving as a user-friendly and inviting forum for the creative exchange of knowledge and ideas, and providing accurate and useful information to the public and the profession.
Henry Schein One announced today that it has acquired Kopfwerk, the leading dental practice management solutions company in Vienna, Austria. Kopfwerk is a full-service software company that delivers state-of-the-art practice management solutions, along with technical support, training, and installation, to boost office productivity, automate clinical and office processes, and enhance patient care.
Founded in 1987 by Peter Schiller and Thomas Gessl, Kopfwerk had 2018 revenues of approximately $2.2 million. Henry Schein expects this transaction to be neutral to its 2019 earnings per share and to be accretive thereafter. Additional financial details and terms were not disclosed.
Henry Schein One is a joint venture between Henry Schein, Inc. and Internet Brands that delivers integrated technology to enhance dental practice management. The company includes Henry Schein’s market-leading solutions of Dentrix, Dentrix Ascend, Dentrix Enterprise, Easy Dental, and TechCentral, as well as international companies, including Software of Excellence, Logiciel Julie, InfoMed, Exan, and LabNet, among others. Also included in Henry Schein One are the dental businesses of Internet Brands, including web-based solutions such as Demandforce, Sesame Communications, Officite, DentalPlans.com and more.
"We are delighted about our new partnership with Kopfwerk. It’s the newest addition to Henry Schein One’s software portfolio and we believe it will further enhance our ability to power successful practices by providing our customers in Austria with the latest in value-added services and technology solutions," said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. "Kopfwerk will bolster our suite of comprehensive solutions that health care professionals rely on to operate a more efficient practice and provide patients with quality care.”
“Kopfwerk will become an integrated part of Henry Schein One’s portfolio of technology solutions, which include the Dentrix family of practice management systems, Easy Dental, Demandforce, Sesame Communications, Officite, and other global companies dedicated to delivering end-to-end management and marketing systems to improve management, profitability, and the entire patient experience,” said James A. Harding Jr., Chief Executive Officer, Henry Schein One. "Kopfwerk’s highly regarded solution will complement these offerings as well as our mission to enable a true digital workflow that helps dental teams become more productive and improve each stage of the patient experience.”
Kopfwerk’s Peter Schiller will continue to serve as General Manager of the Company.
“Henry Schein's excellent reputation and extensive reach among dentists bodes well for our continued success and we are excited to become a part of this team," Mr. Schiller said. “We share with Henry Schein One a commitment to help accelerate the adoption of digital technology and solutions to help dental practices grow and prosper for the ultimate benefit of the patient.”
Henry Schein One, founded in 2018, is the world’s largest dental practice management software company. Headquartered in American Fork, Utah, the company integrated 13 companies, 40 plus software brands, and employs approximately 1,500 people. For more information, visit www.henryscheinone.com
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 18,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides over 1 million customers globally with more than 300 valued solutions that improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items.
A Fortune 500® Company and a member of the S&P 500® and the Nasdaq 100® indexes, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 31 countries. The Company's sales, including the animal health business, reached a record $12.5 billion in 2017, and have grown at a compound annual rate of approximately 15% since Henry Schein became a public company in 1995.
and @HenrySchein on Twitter.
Cautionary Note Regarding Forward-Looking Statements
In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.
Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: effects of a highly competitive and consolidating market; our dependence on third parties for the manufacture and supply of our products; our dependence upon sales personnel, customers, suppliers and manufacturers; our dependence on our senior management; fluctuations in quarterly earnings; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers; general global macro-economic conditions; risks associated with currency fluctuations; risks associated with political and economic uncertainty; disruptions in financial markets; volatility of the market price of our common stock; changes in the health care industry; implementation of health care laws; failure to comply with regulatory requirements and data privacy laws; risks associated with our global operations; transitional challenges associated with acquisitions and joint ventures, including the failure to achieve anticipated synergies; financial risks associated with acquisitions and joint ventures; litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; increased competition by third party online commerce sites; risks from disruption to our information systems; cyberattacks or other privacy or data security breaches; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation. The order in which these factors appear should not be construed to indicate their relative importance or priority.
We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.
The Edison Awards has announced that Dr. Amos Yahav, founder of Augma Biomaterials (www.augmabio.com), has been selected as a 2019 awards finalist for his invention of Bond Apatite®, a new dental material technology that regenerates a patient's own natural bone following implants and other complex oral procedures. The Edison Awards, named after inventor Thomas Alva Edison, recognizes and honors the world's best in innovators and innovations.
"It is a true honor to be recognized as an inventor in the same breath as Thomas Edison and the awards that showcase his greatness," said Dr. Yahav. "As Edison's inventions impacted people's lives forever, we have tried to advance the progress of people's dental/oral health by developing a material that ensures successful outcomes of implants and other complex oral bone augmentation procedures. We thank the Edison Awards for spotlighting Bond Apatite®, a technology that makes these procedures much less invasive, accelerates healing for patients and, most importantly, gives patients their own bone back."
Bond Apatite® is a cement-based material (biphasic calcium sulfate) that is injected into the areas implants or oral bone augmentation restoration procedures are performed, causing a patient's natural bone to regenerate post-procedure (https://bit.ly/2Hnvyis). The Augma Biomaterials - invented product has been successfully used in hundreds of thousands of procedures by thousands of dentists and dental specialists around the world (https://bit.ly/2CCUL2q).
Augma Biomaterials will be at the Edison Awards event in New York City on April 4th (https://bit.ly/1A89urT).
About Augma Biomaterials
Augma Biomaterials is devoted to challenging the status quo by development, production, and marketing of synthetic bone substitutes for the dental market. The company focuses its activity on the development of innovative materials required for bone augmentation, based on a novel technology, scientific knowledge, and extensive research.
Augma Biomaterials has adopted the slogan: It's My Bone, stating its aspiration for finding solutions that help rejuvenate the growth of previously lost bone due to oral bone degradation over time or due to oral trauma. The company's solutions are simple to use and operate, providing the dental surgeon with the best results and thus ultimately contributing to the patients' well-being and satisfaction.
The company's vision is to persist in finding simple solutions for the diverse requirements in the fields of dental implantation and complex surgical procedures.
About the Edison Awards
Established in 1987, the Edison Awards is a program conducted by Edison Universe, a non-profit 501 (c)(3) organization dedicated to fostering future innovators. For more information about the Edison Awards, please visit www.edisonawards.com
The American Academy of Pediatric Dentistry (AAPD), the leading authority on children's oral health, in recognition of National Children's Dental Health Month, announced the release of the second State of Little Teeth Report. This second iteration draws on the latest scientific research and examines the public health crisis of tooth decay among U.S. children through the lens of the current healthcare policy landscape. The report also explores a variety of solutions for pediatric dentists, parents and our nation's leaders.
In 2014, the AAPD issued the first-ever "State of Little Teeth Report," which examined the epidemic of tooth decay among our youngest children, studied the immediate and long-term health, social and economic effects and implications of the federal Affordable Care Act for pediatric oral health, and provided solutions and recommendations for halting the increase of tooth decay in children.
Key findings from the 2019 Report include:
Although the prevalence of tooth decay has decreased overall, there is significant room for improvement. In the U.S., tooth decay affects:
Nearly 1 in 5 children under the age of 5
About half of children aged 6-11
More than half of those aged 12-19
Children living in poverty are twice as likely to suffer from tooth decay, and their dental diseases are more than twice as likely to go untreated as their more affluent peers.
Treatment of severe tooth decay can cost $10,000 per child and up to $25,000 in severe cases, especially if the child needs to be hospitalized and treated under general anesthesia.
Even though more children are visiting the dentist than ever before, many children have difficulty accessing pediatric dental services. Tooth decay in young children continues to be a concern globally, and this public health crisis poses an immediate and long-term threat, not just to the teeth of young children, but to their overall health and development.
"Tooth decay is nearly 100 percent preventable," says Dr. Joseph Castellano, president of the AAPD. "Early dental visits, combined with good dental habits and dietary practices, can slow the decay process in children. In addition, a preventive approach to oral health makes dental care safer, more comfortable and even more affordable. It's our hope that this report provides the basis for a meaningful discussion about the challenges facing the oral health of our children and what we can do about it."
Establishing a Dental Home with a pediatric dentist is key to preventive oral care, and it will lead to beneficial oral health habits for life, as pediatric dentists work to improve children's dental health year round. They actively advocate for children by leading efforts to protect water fluoridation, serving young children through organizations like Head Start, promoting public health activities, and testifying to legislatures on bills affecting access to dental care.
According to this latest report, the tooth decay epidemic can be at least partially remedied by earlier and regularly scheduled dental visits for more children, achieved through advocacy by pediatric dentists, collaboration with primary care medical providers, education for parents, and removal of such barriers as transportation and language that prevent patients from visiting a dentist. Continued reform and improvement of public insurance programs will protect dental visits by children most susceptible to dental disease. As a result of these efforts, more children can enjoy a lifetime of better oral health.
About the American Academy of Pediatric Dentistry
The American Academy of Pediatric Dentistry is the recognized authority on children's oral health. As advocates for children's oral health, the AAPD promotes evidence-based policies and clinical recommendations; educates and informs policymakers, parents and guardians, and other health care professionals; fosters research; and provides continuing professional education for pediatric dentists and general dentists who treat children. Founded in 1947, the AAPD is a not for-profit professional membership association representing the specialty of pediatric dentistry. Its 10,500 members provide primary care and comprehensive dental specialty treatments for infants, children, adolescents and individuals with special health care needs. For further information, visit the AAPD website at http://www.aapd.org or the AAPD's consumer website at http://www.mychildrensteeth.org.
SOURCE American Academy of Pediatric Dentistry
A new and revolutionary chapter for implant dentistry will open this summer in Madrid. At the upcoming Global Symposium, the first of three international events hosted by Nobel Biocare, outstanding developments in the field of implant design and site preparation will be unveiled. Supporting these groundbreaking innovations will be new advancements in implant surface technology as well as long-term implant care.
Leading international clinicians, all experts in their field, will be onsite in Madrid to share their experiences with the new solutions. They will also demonstrate how these can help clinicians to further shorten time-to-teeth and to improve long-term clinical results. Participants will be able to further explore the innovations and more through a number of dedicated hands-on sessions and product demonstrations.
Held at the Marriott Auditorium Hotel & Conference Center from 27-29 June, the Nobel Biocare Global Symposium in Madrid is kicking off the new global event series which was announced last year to extend the originally planned Nobel Biocare Global Symposium 2019 in Las Vegas. Following the meeting in the Spanish capital are two additional Global Symposia in Las Vegas in 2020 as well as in Tokyo in 2021. Through this unique event concept, more dental professionals than ever will be able to experience this new wave of innovations by Nobel Biocare first hand.
Commenting on the upcoming events and launches, Hans Geiselhöringer, President of Nobel Biocare said: “We are excited to welcome dental professionals from all over the world to Madrid in June where we will present the next revolutionary steps in dental implant care with a host of new and forward-thinking innovations. With two more events to come, it will be a once-in-a-generation opportunity to experience true game changers in implant dentistry.”
More information about the Nobel Biocare Global Symposium events series as well as how to register for the kick-off meeting in Madrid can be found online at www.nobelbiocare.com/global-symposia. Dental professionals who already registered for the original Nobel Biocare Global Symposium in Las Vegas will be given the opportunity to transfer their registration to any of the three upcoming events.
Nobel Biocare is a world leader in the field of innovative implant-based dental restorations. The company’s portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, Brånemark System® and NobelReplace®), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), diagnostics, treatment planning and guided surgery solutions (NobelClinician® and DTX Studio™) and biomaterials (creos™). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland. Production takes place at six sites located in the United States, Sweden, Japan and Israel. Products and services are available in over 80 countries through subsidiaries and distributors.
Romexis®, SOTA, and Schick CDR DICOM in Beta, Vatech and Apteryx Beta Testers Welcome
The new Dentrix Smart Image, available with Dentrix G7.0 and higher, is changing the way Dentrix users acquire, locate and view dental images. Smart Image allows you to initiate image acquisitions from the Patient Chart. It then automatically opens and links to your imaging software. Completed images appear in the Patient Charge thumbnail tray for easy search and recall. Completed images are posted to the ledger, while the patient record is also updated to show the date of acquisitions.
Smart Image is already available for Dentsply-Sirona Sidexis 4. Beta testing is underway for Smart Image connectors for Planmeca Romexis®, SOTA Imaging, and Schick CDR DICOM from Dentsply-Sirona. Watch for upcoming newsletter announcements or on https://www.dentrix.com/smartimage for the released versions of these connectors.
Beta testing will begin soon on Smart Image connectors for Vatech and Apteryx. Pracitces who use Vatech and Apteryx should contact firstname.lastname@example.org if they are interested in participating in these Beta tests. Users of Apteryx licensed imaging software from Dentimax, Suni, Datacon, Apex, Smarter Dentist and others should also contact Michelle.
Individuals with physical, cognitive, and developmental disabilities now have a dedicated treatment center in New York City for dental care: NYU College of Dentistry’s Oral Health Center for People with Disabilities.
The 8,000-square-foot center, located in the NYU College of Dentistry’s Weissman Building at 1st Avenue and 24th Street, provides much-needed comprehensive care for patients whose disabilities or medical conditions prevent them from receiving care in a conventional dental setting.
“The NYU Dentistry Oral Health Center for People with Disabilities addresses a major public health challenge by providing comprehensive, compassionate dental care for people with a full range of disabilities who experience significant barriers to accessing care,” said Charles N. Bertolami, DDS, DMedSc, the Herman Robert Fox Dean of the NYU College of Dentistry. “Equally important, care at the center is ongoing. By providing dental care across each patient’s lifespan, the center aims to break the vicious cycle of neglect and repeated hospitalization.”
In New York City alone, an estimated 950,000 people—in a city of 8.5 million—have some form of disability, including 99,000 who use wheelchairs. Research shows that people with disabilities have worse oral health than the general population and are less likely to have access to dental care services.
People with disabilities face many barriers to receiving dental care, including physically accessing dentists’ offices, which may not be able to accommodate wheelchairs or other assistive devices. In addition, some dentists lack confidence in their ability to meet the needs of people with disabilities, so may not be prepared or willing to welcome disabled patients.
As a result, patients with disabilities are often referred to hospitals for dental care because of the need for sedation and may wait as long as six months to get an appointment to be seen in an operating room. These visits are often one-off emergencies without follow-up or continuous preventive care, which can trigger a cycle of recurring dental problems.
“Numerous studies have shown generally poor access to vital health services for both children and adults with disabilities,” said Marco Damiani, chief executive officer of AHRC New York City, one of the largest nonprofits supporting people with disabilities in New York State. “The NYU Dentistry Oral Health Center for People with Disabilities will promote greatly improved access, but it exceeds basic expectations by enabling access to a welcoming state-of-the art facility, dental treatment services from highly experienced and engaged faculty, and a service vision that underscores dignity, respect, and coordination of care.”
Designed for patients with disabilities
The new Oral Health Center for People with Disabilities was designed to meet the unique and diverse needs of people with a range of disabilities. The center was completed through a $12 million renovation by Henningson, Durham & Richardson Architecture and Engineering, P.C. (HDR).
The center features nine spacious patient treatment rooms. In addition, there are two fully equipped sedation suites to provide both inhaled and intravenous sedation administered under the supervision of anesthesiologists.
“Our on-site sedation options eliminate the need for most patients to be referred to hospitals,” said Ronald Kosinski, DMD, clinical director of the Oral Health Center for People with Disabilities and clinical associate professor at NYU College of Dentistry. “In cases where general anesthesia is required, patients can be treated by specially trained NYU Dentistry faculty at one of our hospital affiliates—NYU Langone Health or Bellevue Hospital Center—but remain patients of record at the NYU College of Dentistry.”
A multisensory room, located off of the waiting area, will soon offer patients an immersive environment to reduce their anxiety, help them relax, and engage their senses. The room is being developed in partnership with the NYU Ability Project, an interdisciplinary team of health specialists, engineers, and artists working at the intersection of disability and technology.
Led by Kosinski—a pediatric dentist and specialist in dental anesthesia—the center is staffed by multidisciplinary faculty, a nurse practitioner, a nurse, a social worker, three patient-service representatives, a clinic manager, and a patient care coordinator. Patients are cared for by faculty at NYU College of Dentistry with particular interest and expertise in treating people with disabilities. Senior dental students provide basic dental care not requiring sedation.
In planning for the facility, NYU College of Dentistry collaborated with a number of healthcare and advocacy groups that provide general healthcare and support for people with disabilities, including Cerebral Associations of New York State, Metro Community Health Centers, Family Health Centers at NYU Langone, NYS Office for People with Developmental Disabilities, NYU Langone Health, and the Viscardi Center. In addition, focus groups of people with disabilities were conducted in cooperation with the NYU Ability Project, a collaboration of the Tandon School of Engineering; the Steinhardt School of Culture, Education, and Human Development; and the Tisch School of the Arts.
Training the next generation of dentists specializing in treating people with disabilities
The center builds upon NYU’s long history of educating dental students to care for patients with special needs. NYU College of Dentistry was one of 11 schools funded by the Robert Wood Johnson Foundation in the 1970s to train dental students in caring for people with disabilities.
Since 1971, NYU College of Dentistry has run a successful Special Patient Care Program, an honors program for a small group of exceptional dental students to gain experience working with people with disabilities. Over time, the new center will expand these educational opportunities to all NYU dental students and residents, thereby expanding patient-care delivery.
“The Oral Health Center for People with Disabilities not only offers much-needed clinical services to patients, but also a unique training opportunity for our students. Our goal is to create the next generation of dentists who will practice with competence, confidence, and compassion in providing quality dental care for people with disabilities,” said Bertolami.
About NYU College of Dentistry
Founded in 1865, New York University College of Dentistry (NYU Dentistry) is the third oldest and the largest dental school in the US, educating nearly 10 percent of the nation’s dentists. NYU Dentistry has a significant global reach with a highly diverse student body. Visit http://dental.nyu.edu for more.
University at Buffalo researchers have received part of a $1.5 million grant to investigate light therapy as a replacement for prescription opioids in treating oral mucositis, painful ulcers and swelling in the mouth that result from chemotherapy and radiation treatment for cancer.
Funded by the National Institutes of Dental and Craniofacial Research Small Business Innovation Research program, the grant will help researchers determine the effectiveness of photobiomodulation, a form of low-dose light therapy, in prevention and treatment of oral mucositis after cancer treatment.
The grant was awarded to Cleveland-based MuReva Phototherapy, a spin-off company of lighting solutions manufacturer Lumitex, to further develop the light technology. UB received $511,000 of the award to test the technology.
The research, led by Praveen Arany, DDS, PhD, assistant professor in the UB School of Dental Medicine, will be performed in collaboration with faculty from the Departments of Radiation Medicine and Oral Oncology at Roswell Park Comprehensive Cancer Center.
“The current epidemic of opioids has impacted cancer care, especially for cancer pain relief. This treatment offers a simple, non-drug, non-invasive treatment approach to relieve pain and improve quality of life for cancer patients,” says Arany.
“The striking lab and clinical evidence for photobiomodulation treatments in supportive cancer care has demonstrated tremendous promise and is becoming popular.”
The worst side effect of cancer
Oral mucositis is caused by damage to mucous tissue from chemotherapy or radiation treatment, or stem cell transplant. The condition occurs in close to 40 percent of patients receiving chemotherapy and nearly 80 percent of patients receiving radiation therapy for cancer, according to the Centers for Disease Control. Nearly 70 percent of those receiving stem cell transplants develop mucositis, adds Arany.
Multiple studies have found that patients report oral mucositis as the worst side effect of their cancer treatment. Pain from the condition can slow or delay treatment, and in severe cases require hospitalization and feeding tubes.
“In addition to the pain, it compromises a patient’s ability to eat and swallow, and may even interfere with their planned treatment,” says Mukund Seshadri, DDS, PhD, professor and chair of the Department of Oral Oncology at Roswell Park.
“Given these significant adverse effects on the quality of life in our patients, it is a high priority for us to find new and better ways to prevent or treat this condition.”
“Right now, opioids are the most commonly prescribed drugs to address those symptoms, but they come with a whole host of problematic side effects of their own, including the potential for addiction and abuse,” adds Anurag Singh, MD, professor of oncology and director of radiation research at Roswell Park and professor of medicine in the Jacobs School of Medicine and Biomedical Sciences at UB.
“So we have been looking at a number of ways to treat those symptoms while limiting the need for opioids, including photobiomodulation.”
Light as a solution
Light therapies have existed for decades, but improvements in the technology have made the treatment more affordable for wider use, says Arany.
At a high power, light, often in the form of a laser, is used in medicine to cut or destroy tissue. But at a low level, it has the ability to relieve pain and promote healing.
The effectiveness of photobiomodulation in treating pain and stimulating healing has been documented in hundreds of clinical trials and thousands of academic papers. The treatment is used widely across Europe, Canada, Australia and several other nations. Consensus has not, however, been reached on the proper dosage for the treatment, says Arany.
Using the technology developed by MuReva Phototherapy, UB and Roswell Park researchers will examine the effectiveness of photobiomodulation treatments for oral mucositis, as well as determine the proper dosage to limit pain and stimulate healing in tissues damaged by cancer treatment.
“Current approaches for delivering a photobiomodulation-utilizing laser for oral mucositis requires a physician to spend 30 minutes per patient, per day, and is too impractical an approach for mass adoption,” says Vedang Kothari president and CEO of MuReva Phototherapy.
“MuReva’s innovative mouthpiece that can be self-administered, simultaneously targets a much larger portion of the oral cavity and delivers a full treatment in six minutes or less. We believe this technology has the potential to revolutionize the treatment for oral mucositis and finally present a market-ready solution to this debilitating side-effect.
“We are excited to partner with the University at Buffalo and esteemed clinician and professor Dr. Praveen Arany on this cutting-edge research. We believe that strong industry and academic relationships are important to advance innovative technologies to the marketplace.”
Arany, also president of the World Association for Photobiomodulation Therapy and co-chair of the committee on light therapy for supportive oncology care of the Multinational Association of Supportive Care in Cancer, is an advocate for wider use of photobiomodulation in the United States.
He recently took part in the first Congressional briefing on photobiomodulation before the House Science, Space and Technology Committee in Washington, D.C. The briefing, held on Oct. 11, 2018, invited a panel of international experts on the therapy to discuss the potential of photobiomodulation to improve health care and lower dependence on opioids.
“The ability of low-dose light therapy to promote healing has been established since the 1960s,” says Arany.
“A major obstacle with its wide spread use has been a lack of understanding of its precise biological mechanism. Recent work from our group has outlined both therapeutic and dose-limiting molecular pathways that are aiding development of safe and efficacious clinical protocols.”
Newport Beach, CA: The ALPHAEON CREDIT card, offered through Comenity Capital Bank, has become one of the fastest growing patient financing solutions for plastic surgeons, dermatologists, and ophthalmologists over the last five years.
Starting in 2019, ALPHAEON CREDIT is pleased to announce they are now adding dentists to their rapidly expanding network of offices.
ALPHAEON CREDIT offers patients a revolving line of credit with promotional financing including no interest if paid in full and equal payment plans. In comparison to other patient financing options, dental offices will appreciateALPHAEON CREDIT’s ability to provide:
Stronger approval rates so more patients can move forward with the treatments dentists recommend and patients want
Superior credit limitsup to $25,000 so patients can finance the full cost of their treatment and reuse their line of credit for additional services
Stress-free service with an intuitive platform, less paperwork, and an exceptional support team committed to answering all calls from an office immediately
Dental offices can trust ALPHAEON CREDIT. Their leadership team has twenty-five years of experience in dentistry and seventy-five years of experience in patient financing. They understand the unique needs of dentists and built a patient financing solution that will help the most patients.
For more information on ALPHAEON CREDIT for dentists, please all Anne Haines, Director of Dental Financing, at (724) 216-3733 or at email@example.com.